BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 14640919)

  • 1. Systemic chemotherapy in the treatment of malignant melanoma.
    Lens MB; Eisen TG
    Expert Opin Pharmacother; 2003 Dec; 4(12):2205-11. PubMed ID: 14640919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha.
    Vuoristo M; Gröhn P; Kumpulainen E; Korpela M
    Eur J Cancer; 1994; 30A(3):420. PubMed ID: 7515632
    [No Abstract]   [Full Text] [Related]  

  • 4. [Chemotherapy of malignant melanoma].
    Jedrzejczak WW
    Pol Arch Med Wewn; 1998 Oct; 100(4):294-9. PubMed ID: 10335037
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
    Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
    Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
    Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH
    Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic chemotherapy for the treatment of metastatic melanoma.
    Li Y; McClay EF
    Semin Oncol; 2002 Oct; 29(5):413-26. PubMed ID: 12407507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
    Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S
    Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
    Chapman PB; Einhorn LH; Meyers ML; Saxman S; Destro AN; Panageas KS; Begg CB; Agarwala SS; Schuchter LM; Ernstoff MS; Houghton AN; Kirkwood JM
    J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
    Atkins MB; Hsu J; Lee S; Cohen GI; Flaherty LE; Sosman JA; Sondak VK; Kirkwood JM;
    J Clin Oncol; 2008 Dec; 26(35):5748-54. PubMed ID: 19001327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
    Aranha GV; Grage TB
    Minn Med; 1977 Aug; 60(8):543-8. PubMed ID: 882082
    [No Abstract]   [Full Text] [Related]  

  • 13. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Legha SS
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
    J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
    Jelić S; Babovic N; Kovcin V; Milicevic N; Milanovic N; Popov I; Radosavljevic D
    Melanoma Res; 2002 Feb; 12(1):91-8. PubMed ID: 11828263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemotherapy for advanced melanoma: maybe it is real.
    Khayat D; Bernard-Marty C; Meric JB; Rixe O
    J Clin Oncol; 2002 May; 20(10):2411-4. PubMed ID: 12011117
    [No Abstract]   [Full Text] [Related]  

  • 17. Bacterial Sepsis Increases Survival in Metastatic Melanoma: Chlamydophila Pneumoniae Induces Macrophage Polarization and Tumor Regression.
    Buzás K; Marton A; Vizler C; Gyukity-Sebestyén E; Harmati M; Nagy K; Zvara Á; Katona RL; Tubak V; Endrész V; Németh IB; Oláh J; Vígh L; Bíró T; Kemény L
    J Invest Dermatol; 2016 Apr; 136(4):862-865. PubMed ID: 26743601
    [No Abstract]   [Full Text] [Related]  

  • 18. What can we learn from phase II adjuvant trials in melanoma?
    Keilholz U; Suciu S; Eggermont AM
    Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha.
    Mattila K; Raanta P; Lahtela V; Pyrhönen S; Koskivuo I; Vihinen P
    Anticancer Res; 2018 Nov; 38(11):6393-6397. PubMed ID: 30396963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T
    Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.